Abstract: Heart failure is the terminal stage of many heart diseases, most of which are patients with reduced ejection fraction. The efficacy of drug therapy for these patients is still limited. However, heart transplantation has not been widely carried out in clinic due to its high price, limited donors and postoperative rejection. In recent years, the development of instrumentation therapy has brought about a breakthrough in the treatment of such patients with heart failure. In this review, we introduce the principle, design, clinical trial results and recent progress of two new implantable devices for the treatment of HFrEF patients, cardiac contractility modulation (CCM) and baroreflex activation therapy (BAT), and discuss their research directions and challenges.